Cardiovascular risk factors among patients with schizophrenia, bipolar, depressive, anxiety, and personality disorders

European Psychiatry

Volumn 35, Issue , 2016, Pages 8-15

  Perez Pinar M ^a   Mathur, R ^b   Foguet, Q ^c   Ayis, S ^d   Robson, J ^b   Ayerbe, L ^a,b  

^a The Westborough Road Health Centre   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antidepressive agents; Antipsychotic agents; Cardiovascular diseases; Cohort studies; Schizophrenia; Socioeconomic factors

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMPARATIVE STUDY; DEMOGRAPHY; DEPRESSION; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERSONALITY DISORDER; PHYSICAL INACTIVITY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIAL ISOLATION; TOBACCO CONSUMPTION; UNITED KINGDOM; AGED; CARDIOVASCULAR DISEASE; COMORBIDITY; ENGLAND; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; BIPOLAR DISORDER; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; LONDON; MALE; MIDDLE AGED; PERSONALITY DISORDERS; RISK FACTORS; SCHIZOPHRENIA;

EID: 84962477130     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2016.02.004     Document Type: Article

References (45)

1. Colton C.W., Manderscheid R.W. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006, 3(2):A42.
2. Viron M.J., Stern T.A. The impact of serious mental illness on health and healthcare. Psychosomatics 2010, 51(6):458-465.
3. Osborn D.P., Wright C.A., Levy G., King M.B., Deo R., Nazareth I. Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis. BMC Psychiatry 2008, 8:84.
4. Stubbs B., Williams J., Gaughran F., Craig T. How sedentary are people with psychosis? A systematic review and meta-analysis. Schizophr Res 2016, 171(1-3.).
5. De Leon J., Diaz F.J. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005, 76(2-3):135-157.
6. Meng L., Chen D., Yang Y., Zheng Y., Hui R. Depression increases the risk of hypertension incidence: a meta-analysis of prospective cohort studies. J Hypertens 2012, 30(5):842-851.
7. Vancampfort D., Stubbs B., Mitchell A.J., De Hert M., Wampers M., Ward P.B., et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 2015, 14(3):339-347.
8. Vancampfort D., Mitchell A.J., De Hert M., Sienaert P., Probst M., Buys R., et al. Type 2 Diabetes in patients with major depressive disorder: a meta-analysis of prevalence estimates and predictors. Depress Anxiety 2015, 32(10):763-773.
9. Stubbs B., Vancampfort D., De Hert M., Mitchell A.J. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr Scand 2015, 132(2):144-157.
10. Vancampfort D., Mitchell A.J., De Hert M., Sienaert P., Probst M., Buys R., et al. Prevalence and predictors of type 2 diabetes mellitus in people with bipolar disorder: a systematic review and meta-analysis. J Clin Psychiatry 2015, 76(11):1490-1499.
11. Correll C.U., Detraux J., De Lepeleire J., De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 2015, 14(2):119-136.
12. Andersohn F., Schade R., Suissa S., Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009, 166(5):591-598.
13. Grossman E., Messerli F.H. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 2012, 125(1):14-22.
14. Galling B., Roldán A., Nielsen R.E., Nielsen J., Gerhard T., Carbon M., et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiatry 2016, 73(3):247-259.
15. Addo J., Ayerbe L., Mohan K.M., Crichton S., Sheldenkar A., Chen R., et al. Socioeconomic status and stroke: an updated review. Stroke 2012, 43(4):1186-1191.
16. Rao S.V., Kaul P., Newby L.K., Lincoff A.M., Hochman J., Harrington R.A., et al. Poverty, process of care, and outcome in acute coronary syndromes. J Am Coll Cardiol 2003, 41(11):1948-1954.
17. Patel V., Lund C., Hatherill S., Plagerson S., Corrigall J., Funk M., et al. Equity, social determinants and public health programmes 2010, 115-134. World Health Organization, Geneva. E. Blas, A.S. Kurup (Eds.).
18. Gallo V., Egger M., McCormack V., Farmer P.B., Ioannidis J.P., Kirsch-Volders M., et al. Strengthening the reporting of observational studies in epidemiology-molecular epidemiology (STROBE-ME): an extension of the STROBE Statement. PLoS Med 2011, 8:e1001117.
19. Perk J., De Backer G., Gohlke H., Graham I., Reiner Z., Verschuren M., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012, 33(13):1635-1701.
20. NICE Pathways. Cardiovascular disease prevention 2016, [Available from: http://www.pathways.nice.org.uk/pathways/cardiovascular-disease-prevention; accessed February 2016].
21. Jarman B., Townsend P., Carstairs V. Deprivation indices. BMJ 1991, 303(6801):523.
22. British National Formulary 2015, [Available from: http://www.medicinescomplete.com/mc/bnf/current/; accessed December 2015].
23. Eckel R.H., Jakicic J.M., Ard J.D., de Jesus J.M., Houston Miller N., Hubbard V.S., et al. AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014, 63(25 Pt B):2960-2984.
24. Mitchell A.J., Vaze A., Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet 2009, 22(374):609-619.
25. Osborn D.P., Baio G., Walters K., Petersen I., Limburg H., Raine R., et al. Inequalities in the provision of cardiovascular screening to people with severe mental illnesses in primary care: cohort study in the United Kingdom THIN Primary Care Database 2000-2007. Schizophr Res 2011, 129(2-3):104-110.
26. Quality and Outcomes Framework. NHS The Information Centre [Available on: ; accessed November 2015]. http://www.qof.ic.nhs.uk/.
27. Chaiton M.O., Cohen J.E., O'Loughlin J., Rehm J. A systematic review of longitudinal studies on the association between depression and smoking in adolescents. BMC Public Health 2009, 22(9):356.
28. Hasan S.S., Clavarino A.M., Mamun A.A., Kairuz T. Incidence and risk of diabetes mellitus associated with depressive symptoms in adults: evidence from longitudinal studies. Diabetes Metab Syndr 2014, 8(2):82-87.
29. Luppino F.S., de Wit L.M., Bouvy P.F., Stijnen T., Cuijpers P., Penninx B.W., et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010, 67:220-229.
30. Stahl S. Essential psychopharmacology 2013, Cambridge University Press, New York.
31. Miron I.C., Baroană V.C., Popescu F., Ionică F. Pharmacological mechanisms underlying the association of antipsychotics with metabolic disorders. Curr Health Sci J 2014, 40(1):12-17.
32. Hughes J.R., Stead L.F., Hartmann-Boyce J., Cahill K., Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2014, 1:Cd000031.
33. Chapman S., Ragg M., McGeechan K. Citation bias in reported smoking prevalence in people with schizophrenia. Aust N Z J Psychiatry 2009, 43(3):277-282.
34. Soundy A., Roskell C., Stubbs B., Vancampfort D. Selection, use and psychometric properties of physical activity measures to assess individuals with severe mental illness: a narrative synthesis. Arch Psychiatr Nurs 2014, 28(2):135-151.
35. Mitchell A.J., Vancampfort D., De Hert M., Stubbs B. Do people with mental illness receive adequate smoking cessation advice? A systematic review and meta-analysis. Gen Hosp Psychiatry 2015, 37(1):14-23.
36. Foguet i Boreu Q. Physical health and severe mental illness 2012, Butlletí de la Medicina de Familia a Catalunya, Barcelona, [Available from: http://www.pub.bsalut.net/butlleti/vol30/iss2/5; accessed February 2016].
37. Fernández-San-Martín M.I., Martín-López L.M., Masa-Font R., Olona-Tabueña N., Roman Y., Martin-Royo J., et al. The effectiveness of lifestyle interventions to reduce cardiovascular risk in patients with severe mental disorders: meta-analysis of intervention studies. Community Ment Health J 2014, 50(1):81-95.
38. Firth J., Cotter J., Elliott R., French P., Yung A.R. Systematic review and meta-analysis of exercise interventions in schizophrenia patients. Psychol Med 2015, 45(7):1343-1361.
39. Bennett M.E., Wilson A.L., Genderson M., Saperstein A.M. Smoking cessation in people with schizophrenia. Curr Drug Abuse Rev 2013, 6(3):180-190.
40. Kennedy E., Kumar A., Datta S.S. Antipsychotic medication for childhood-onset schizophrenia. Cochrane Database Syst Rev 2007, 3:Cd004027.
41. Arroll B., Elley C.R., Fishman T., Goodyear-Smith F.A., Kenealy T., Blashki G., et al. Antidepressants versus placebo for depression in primary care. Cochrane Database Syst Rev 2009, Cd007954. 10.1002/14651858.
42. Kapczinski F., dos S.S.J.J., Batista MdCAA, Schmitt R.R. Antidepressants for generalised anxiety disorder (GAD). Cochrane Database Syst Rev 2003, 2:CD003592.
43. Mottram P., Wilson K., Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev 2006, 1:Cd003491.
44. Marriott R.G., Neil W., Waddingham S. Antipsychotic medication for elderly people with schizophrenia. Cochrane Database Syst Rev 2006, 1:Cd005580.
45. Essali A., Ali G. Antipsychotic drug treatment for elderly people with late-onset schizophrenia. Cochrane Database Syst Rev 2012, 2:Cd004162.